Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also offers Renevia, a facial aesthetics product. In addition, the company engages in the research and development of therapeutic products for retinal diseases, neurological diseases, and disorders and oncology. Lineage Cell Therapeutics, Inc. has a collaboration with Orbit Biomedical, Ltd. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.

Paul Segall

Judith Segall

Michael D West

Lineage Cell Therapeutics, Inc.

AgelessRx provides anti-aging treatments supported by longevity science. The organization offers various therapies to assist individuals in managing health concerns related to aging.

AgelessRx

BioSenic S.A., a biotech company, focuses on developing clinical assets. Its technologies include cutting-edge allogeneic cell and gene therapy platform with differentiated bone marrow sourced mesenchymal stromal cells, which can be stored at the point of use in the hospital; and Arsenic TriOxide platform for use in immuno-oncology to treat graft-versus-host disease, systemic lupus erythematosus, and systemic sclerosis. The company's investigational medicinal product is ALLOB, which is in a Phase IIb clinical trial in patients with difficult tibial fractures. The company is based in Mont-Saint-Guibert, Belgium.

BioSenic S.A.

Brooklyn ImmunoTherapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Its advanced program is IRX-2 that is in a Phase 2b clinical trial in patients with squamous cell cancer of the head and neck. The company also develops therapies using gene-editing and cell therapy technology for the treatment of oncology, blood disorder, and monogenic disease. Brooklyn ImmunoTherapeutics, Inc. is based in Brooklyn, New York.

Eterna Therapeutics Inc.

Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its proprietary cell-based therapy platform and associated development and manufacturing capabilities. With this platform Lineage develops and manufactures specialized, terminally-differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed either to replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Lineage’s clinical assets include (i) OpRegen®, a retinal pigment epithelium transplant therapy in Phase I/IIa development for the treatment of dry age-related macular degeneration, a leading cause of blindness in the developed world; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase I/IIa development for the treatment of acute spinal cord injuries; and (iii) VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells currently in Phase I development for the treatment of non-small cell lung cancer. For more information, please visit www.lineagecell.com. 

Metric
Company Name	Lineage Cell Therapeutics, Inc.	AgelessRx	BioSenic S.A.	Eterna Therapeutics Inc.
Symbol	LCTX		BIOS	ERNA
MSH ID	COM:LINEAGECELL	COM:AGELESSRX	COM:BIOSENIC	COM:ETERNATX
Market	STOCKS	PRIVATE	STOCKS	STOCKS
Sector	Healthcare	Healthcare & Health Services	Healthcare	Healthcare
Industry	Biotechnology	Medical Services	Biotechnology	Biotechnology
Country	US	US	BE	US
Stage
Employee Count	68		12	8
Website	lineagecell.com	agelessrx.com	biosenic.com	brooklynitx.com
LinkedIn	lineagecell
Founders

Metric
Market Cap	180.52M	3.69M	9.90M
Enterprise Value
Monthly Web Traffic			270.57K
Web Traffic Growth			0.55
Valuation
Raised Capital

Metric
Revenue	8.95M	68K
Revenue (LTM)
Revenue (NTM)
Gross Profit	7.58M	-1.29M
EBITDA	-24.04M	-19.55M
Operating Income	-24.73M	-20.67M
Net Income	-21.49M	-21.67M
EPS	-0.12	-4.08
Diluted EPS	-0.12	-4.08
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.91	-5.88
Operating Profit Margin	-2.77	-135.73
EBITDA Margin	-2.69	-287.51
Net Profit Margin	-2.41	-147.65
Return on Equity	-0.31	15.58
Return on Assets	-0.21	-0.44
Return on Capital Employed	-0.27	-0.50

COM:LINEAGECELL

Lineage Cell Therapeutics, Inc.

Last Close

0.60

22/11 21:00

Market Cap

180.52M

Beta: -

Volume Today

2.48K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-7.64	-0.42
P/B Ratio	2.62	2.34
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	28.94	192.73
EV Multiple	-7.37	2.09

Metric
Days Sales Outstanding	17.98	12.71K
Days Payables Outstanding	1.72K	4.45K
Days Inventory Outstanding
Operating Cycle	30.40	2.28K
Cash Conversion Cycle	13.87	1.79K
Asset Turnover	0.09	0.00

Metric
Operating Cash Flow	-28.57M	-20.41M
Free Cash Flow	-29.24M	-20.43M
Cash Flow to Debt	-5.71	-0.38
Operating Cash Flow/Sales	-2.72	-101.81
Free Cash Flow Yield	-0.18	-2.54

Metric
Cash & Equivalents	35.44M	7.58M
Accounts Receivable	-446K	527K
Inventory
Goodwill	10.67M	2.04M
Debt to Capitalization	0.04	2.84
Debt to Assets	0.03	0.79
Current Ratio	2.74	0.73
Quick Ratio	2.71	1.22

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.52	28.90
R&D to Revenue	1.81	130.82
SG&A to Revenue	1.98	252.08